Insulin human - Biologic Drug Details

Summary for insulin human

Tradenames:	5
High Confidence Patents:	10
Applicants:	4
BLAs:	4
Suppliers: see list	5
Recent Clinical Trials:	See clinical trials for insulin human

Recent Clinical Trials for insulin human

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Eurofarma Laboratorios S.A.	PHASE3
Wake Forest University Health Sciences	PHASE3
National Institutes of Health (NIH)	EARLY_PHASE1

See all insulin human clinical trials

Pharmacology for insulin human

Established Pharmacologic Class	Insulin
Chemical Structure	Insulin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for insulin human Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for insulin human Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938	5,462,535	2014-10-14	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938	5,626,566	2014-03-24	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938	5,693,027	2014-09-26	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938	5,980,491	2017-07-03	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938	6,074,372	2018-06-03	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for insulin human Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	10,004,686	2033-06-12	Patent claims search
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	10,220,075	2036-05-19	Patent claims search
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	10,220,076	2035-05-15	Patent claims search
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	10,259,856	2035-04-14	Patent claims search
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	10,272,050	2035-10-14	Patent claims search

International Patents for insulin human

Country	Patent Number	Estimated Expiration
Japan	H07500039
Germany	69724784
South Korea	101558026
Australia	2010259943
Israel	216910

Supplementary Protection Certificates for insulin human

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
301288	Netherlands		PRODUCT NAME: VONICOG ALFA; REGISTRATION NO/DATE: NOT AVAILABLE
CA 2024 00033	Denmark		PRODUCT NAME: VONICOG ALFA; REG. NO/DATE: EU/1/18/1298 20180904

Insulin human Market Analysis and Financial Projection

Last updated: February 15, 2026

Market Dynamics for Human Insulin

Market Size and Growth Trends

The global human insulin market was valued at approximately $21 billion in 2022 and is projected to reach $29 billion by 2030, growing at a compound annual growth rate (CAGR) of 4.5% (1). The growth rate reflects increased diabetes prevalence, especially type 1 and type 2, coupled with the rising adoption of insulin therapy worldwide.

Driving Factors

• Diabetes Prevalence: Around 537 million adults lived with diabetes as of 2021, expected to grow to 643 million by 2030 (2).
• Treatment Adoption: Insulin remains the primary therapy for type 1 diabetes and advanced stages of type 2 diabetes (3).
• Biologic Competition: Human insulin faces competition from insulin analogs, which offer improved pharmacokinetics but at higher costs.

Market Challenges

• Cost and Affordability: Human insulin remains less expensive than analogs but still confronts price pressures and reimbursement issues.
• Manufacturing Complexity: Biologic production requires sophisticated facilities, limiting generic or biosimilar competition.
• Patent Landscape: Key patents on insulin analogs extend competitive barriers through 2030, maintaining market dominance for branded products.

Geographical Factors

North America holds the largest market share (~45%), driven by high diabetes prevalence and healthcare infrastructure (4). The Asia-Pacific region exhibits rapid growth due to increasing rates of diabetes and improving healthcare access.

---

Financial Trajectory of Human Insulin

Revenue Contributions

Major companies like Novo Nordisk, Eli Lilly, and Sanofi generate combined revenues exceeding $20 billion annually from insulin products. Human insulin accounts for about 40-50% of these insulin revenue streams, with the remainder attributable to analogs.

Company	Estimated Human Insulin Revenue (2022)	Percentage of Total Insulin Revenue
Novo Nordisk	$4.2 billion	45%
Eli Lilly	$2.1 billion	40%
Sanofi	$3.1 billion	50%

Cost Margins

Margins for human insulin are lower than for analogs due to competitive pricing. Estimated gross margins for human insulin hover around 25-35%, versus 50-60% for analogs.

R&D and CapEx

R&D expenditures are primarily invested in developing biosimilars and improving manufacturing processes. Capital expenditure on manufacturing facilities for human insulin averages around $100 million per plant, with ongoing investments extending through 2025.

Impact of Biosimilar Entry

Biosimilar human insulin products have entered European markets, causing price reductions up to 30%. Entry in the U.S. remains limited due to regulatory and patent barriers, but market share erosion is anticipated as biosimilar approvals increase (5).

---

Regulatory and Policy Outlook

• Biosimilar Pathways: The FDA approved the first biosimilar insulin, Basaglar (1996), in 2015. Several others follow, pressuring traditional manufacturers (6).
• Pricing Policies: The U.S. government is considering policies to cap insulin prices, which could restrict revenue growth.
• Patent Expiry Timeline: Key patents for insulin analogs expire between 2024 and 2030, opening pathways for biosimilars and generics.

---

Strategic Implications

• Manufacturing Innovation: Companies invest heavily in low-cost biosimilar production to capture market share.
• Pricing Strategies: Price reduction and benefit from economies of scale are essential to retain competitiveness.
• Pipeline Development: Focus shifts to biosimilar insulin and novel delivery devices, which may reshape the landscape over the next decade.

---

Key Takeaways

• The human insulin market is projected to grow steadily, driven by rising diabetes prevalence.
• Revenue is concentrated among large biopharma companies, with margins under pressure.
• Patent expiries and biosimilar entries are key factors influencing future pricing and market share.
• Regulatory policies and healthcare reforms will impact access, pricing, and competition.
• Innovation in biosimilar manufacturing and delivery systems offers growth opportunities.

---

FAQs

1. How does the cost of human insulin compare globally?
Prices vary significantly, with high-income countries paying higher retail prices, whereas some emerging markets benefit from lower costs due to government negotiations and local manufacturing.

2. Are biosimilar insulins expected to replace originator products?
Biosimilars are gaining market share, especially in Europe, but face regulatory and trust barriers in the U.S. They will likely coexist with originator products for the foreseeable future.

3. What is the status of R&D for insulin delivery devices?
Multiple companies invest in innovative pens, pumps, and minimally invasive delivery systems to improve patient compliance and adherence.

4. How might policy changes affect the commercial outlook?
Potential price caps and reimbursement reforms could suppress revenue growth and incentivize cost-effective biosimilar development.

5. What opportunities exist for new entrants?
Low-cost biosimilar manufacturing, innovative delivery systems, and targeted formulations present entry points, especially in regions with unmet demand.

---

References

1. MarketsandMarkets, "Insulin Market by Product," 2022.
2. International Diabetes Federation, "IDF Diabetes Atlas," 2021.
3. American Diabetes Association, "Standards of Medical Care in Diabetes," 2022.
4. IQVIA, "Global Insulin Sales Data," 2022.
5. U.S. Food and Drug Administration, "Biosimilar Insulin Approvals," 2022.
6. European Medicines Agency, "Biosimilar Products," 2022.